Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Co. Ltd.

www.daiichisankyo.com

Latest From Daiichi Sankyo Co. Ltd.

New Drug Launches Worldwide Dipped In 2019

The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.

Companies Innovation

Keeping Track: Targeted Oncologics Take Center Stage, Led By Retevmo And Tabrecta Approvals

The latest oncology news and highlights from the Pink Sheet’s FDA Performance Tracker.

US FDA Performance Tracker Cancer

Q1 Sales & Earnings: An Opportunity For Clarity In An Uncertain Time

Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.

Coronavirus COVID-19 Sales & Earnings

Daiichi Sankyo Enters Europe's Cholesterol Market

The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.

Cardiovascular Approvals
See All

Company Information

UsernamePublicRestriction

Register